RADIUS HEALTH, INC. (NASDAQ:RDUS) Files An 8-K Financial Statements and Exhibits

RADIUS HEALTH, INC. (NASDAQ:RDUS) Files An 8-K Financial Statements and Exhibits
Item 9.01

Story continues below

Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.

Description

99.1

Press Release dated July 21, 2017.


Radius Health, Inc. Exhibit
EX-99.1 2 rdus-ex991_6.htm EX-99.1 rdus-ex991_6.htm Exhibit 99.1     Radius Health Announces that the Committee for Medicinal Products for Human Use (CHMP) Has Issued a Second Day-180 List of Outstanding Issues in its Regulatory Review of Eladynos™ (Abaloparatide-SC),…
To view the full exhibit click here

About RADIUS HEALTH, INC. (NASDAQ:RDUS)

Radius Health, Inc. is a biopharmaceutical company focused on developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. Its product candidate, the investigational drug abaloparatide for subcutaneous injection, has completed Phase III development for use in the reduction of fracture risk in postmenopausal women with osteoporosis. Its clinical pipeline also includes an investigational abaloparatide transdermal patch for use in osteoporosis and the investigational drug RAD1901 for use in hormone-driven and hormone-resistant breast cancer, and vasomotor symptoms in postmenopausal women. Its preclinical pipeline includes RAD140, a non-steroidal, selective androgen receptor modulator (SARM) under investigation for use in cancer.

An ad to help with our costs